MEU
0.115
62%
FBR
0.004
-20%
PL9
0.009
28.6%
NOR
0.013
-18.8%
MRQ
0.005
25%
A11
0.165
-15.4%
AXI
0.016
23.1%
TNY
0.085
-15%
BLU
0.006
20%
M4M
0.006
-14.3%
MGU
0.006
20%
NFL
0.12
-14.3%
GLL
0.007
16.7%
TEM
0.006
-14.3%
RRE
0.265
15.2%
AUV
0.014
-12.5%
FCT
0.009
12.5%
NES
0.007
-12.5%
RR1
0.009
12.5%
ATH
0.008
-11.1%
IMB
0.61
11.9%
UNT
0.008
-11.1%
DTR
0.235
11.9%
OR3
0.06
-10.4%
JPR
0.029
11.5%
BOA
0.028
-9.7%
FEX
0.485
11.5%
T92
0.041
-8.9%
AAU
0.01
11.1%
SBM
0.512
-8.6%
PCK
0.35
11.1%
M79
0.11
-8.3%
MYR
0.455
11%
MTB
0.011
-8.3%
AVR
7.65
10.9%
AVM
0.115
-8%
AGR
0.021
10.5%
YRL
0.25
-7.4%
IOD
0.165
10%
AQD
0.051
-7.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts